A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

被引:30
|
作者
Alibhai, Shabbir M. H. [1 ,6 ]
Santa Mina, Daniel [1 ,2 ]
Ritvo, Paul [2 ]
Tomlinson, George [1 ,2 ]
Sabiston, Catherine [3 ]
Krahn, Murray [1 ,2 ]
Durbano, Sara [1 ]
Matthew, Andrew [1 ]
Warde, Padraig [1 ,2 ,3 ]
O'Neill, Meagan [1 ]
Timilshina, Narhari [1 ]
Segal, Roanne [4 ]
Culos-Reed, Nicole [5 ]
机构
[1] Univ Toronto, Univ Hlth Network, Toronto, ON M5G 2C4, Canada
[2] York Univ, Canc Care Ontario, Toronto, ON M3J 1P3, Canada
[3] Univ Toronto, Toronto, ON M5S 2J7, Canada
[4] Univ Ottawa, Ottawa Hosp, Ctr Canc, Ottawa, ON K1N 6N5, Canada
[5] Univ Calgary, Calgary, AB T2N 1N4, Canada
[6] Toronto Gen Hosp, 200 Elizabeth St Room EN14-214, Toronto, ON M5G 2C4, Canada
关键词
Androgen deprivation therapy; Cost-effectiveness; Exercise; Fatigue; Patient adherence; Physical fitness; Prostate cancer; Quality of life; Randomized controlled trial; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; FUNCTIONAL ASSESSMENT; RESISTANCE EXERCISE; SUPPRESSION THERAPY; AEROBIC EXERCISE; PROGRAM; INTERVENTION; PERFORMANCE; PREVALENCE;
D O I
10.1186/s12885-018-5189-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundExisting evidence demonstrates that 1:1 personal training (PT) improves many adverse effects of androgen deprivation therapy (ADT). Whether less resource-intensive exercise delivery models are as effective remains to be established. We determined the feasibility of conducting a multi-center non-inferiority randomized controlled trial comparing PT with supervised group (GROUP) and home-based (HOME) exercise programs, and obtained preliminary efficacy estimates for GROUP and HOME compared to PT on quality of life (QOL) and physical fitness.MethodsMen with prostate cancer on ADT were recruited from one of two experienced Canadian centres and randomized 1:1:1 to PT, GROUP, or HOME. Randomization was stratified by length of ADT use and site. Participants completed moderate intensity aerobic and resistance exercises 4-5days per week for 6 months with a target 150min per week of exercise. Exercise prescriptions were individualized and progressed throughout the trial. Feasibility endpoints included recruitment, retention, adherence, and participant satisfaction. The efficacy endpoints QOL, fatigue, and fitness (VO2 peak, grip strength, and timed chair stands) in GROUP and HOME were compared for non-inferiority to PT. Descriptive analyses were used for feasibility endpoints. Between-group differences for efficacy endpoints were examined using Bayesian linear mixed effects models.ResultsFifty-nine participants (mean age 69.9years) were enrolled. The recruitment rate was 25.4% and recruitment was slower than projected. Retention was 71.2%. Exercise adherence as measured through attendance was high for supervised sessions but under 50% by self-report and accelerometry. Satisfaction was high and there was no difference in this measure between all three groups. Between-group differences (comparing both GROUP and HOME to PT) were smaller than the minimum clinically important difference on most measures of QOL, fatigue, and fitness. However, two of six outcomes for GROUP and four of six outcomes for HOME had a>20% probability of being inferior for GROUP.ConclusionsFeasibility endpoints were generally met. Both GROUP and HOME interventions in men with PC on ADT appeared to be similar to PT for multiple efficacy outcomes, although conclusions are limited by a small sample size and cost considerations have not been incorporated. Efforts need to be targeted to improving recruitment and adherence. A larger trial is warranted.Trial registrationClinicalTrials.gov:NCT02046837. Date of registration: January 20, 2014.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
    C Ellen Lee
    William D Leslie
    YK James Lau
    BMC Cancer, 12
  • [22] Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer
    Angela S. Alberga
    Roanne J. Segal
    Robert D. Reid
    Chris G. Scott
    Ronald J. Sigal
    Farah Khandwala
    James Jaffey
    George A. Wells
    Glen P. Kenny
    Supportive Care in Cancer, 2012, 20 : 971 - 981
  • [23] MUSCULOSKELETAL EFFECTS OF EXERCISE IN MEN WITH PROSTATE CANCER INITIATING ANDROGEN DEPRIVATION THERAPY
    Newton, Robert U.
    Galvao, Daniel A.
    Spry, Nigel
    Cormie, Prue
    Chambers, Suzanne K.
    Gardiner, Robert A.
    Shum, David H.
    Joseph, David
    Taaffe, Dennis R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 206 - 207
  • [24] A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
    Lee, C. Ellen
    Leslie, William D.
    Lau, Y. K. James
    BMC CANCER, 2012, 12
  • [25] Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
    McKay, Rana R.
    Xie, Wanling
    Ye, Huihui
    Fennessy, Fiona M.
    Zhang, Zhenwei
    Lis, Rosina
    Calagua, Carla
    Rathkopf, Dana
    Laudone, Vincent P.
    Bubley, Glenn J.
    Einstein, David J.
    Chang, Peter K.
    Wagner, Andrew A.
    Parsons, J. Kellogg
    Preston, Mark A.
    Kilbridge, Kerry
    Chang, Steven L.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Trinh, Quoc-Dien
    Kibel, Adam S.
    Taplin, Mary-Ellen
    JOURNAL OF UROLOGY, 2021, 206 (01): : 80 - 87
  • [26] Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
    Antonarakis, Emmanuel S.
    Kibel, Adam S.
    Yu, Evan Y.
    Karsh, Lawrence I.
    Elfiky, Aymen
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Corman, John M.
    Millard, Frederick E.
    Maher, Johnathan C.
    Chang, Nancy N.
    DeVries, Todd
    Sheikh, Nadeem A.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2451 - 2459
  • [27] Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer
    Conde-Moreno, A. J.
    Lopez, F.
    Hervas, A.
    Morillo, V.
    Mendez, A.
    Puertas, M. D. M.
    Valero Albarran, J.
    Gomez De Iturriaga, A.
    Rico, M.
    Vazquez de la Torre, M. L.
    Samper Ots, P. M.
    Perez Romasanta, L. A.
    Pastor Peidro, J.
    Ibanez, C.
    Ferrer, F.
    Zapatero, A.
    Anchuelo, J.
    Rodriguez, A.
    Albiach, C. F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S59 - S59
  • [28] A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer.
    Fizazi, K.
    Powles, T.
    George, D. J.
    Poehlein, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] A phase II randomized controlled trial of exercise on biochemical progression in men with prostate cancer on active surveillance.
    Kang, Dong-Woo
    Fairey, Adrian S.
    Boule, Normand G.
    Field, Catherine J.
    Wharton, Stephanie A.
    Courneya, Kerry S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial
    Usmani, Nawaid
    Ghosh, Sunita
    Sanghera, Karan P.
    Ong, Aldrich D.
    Koul, Rashmi
    Dubey, Arbind
    Ahmed, Shahida
    Quon, Harvey
    Yee, Don
    Parliament, Matthew
    Sivananthan, Gokulan
    Hunter, William
    Danielson, Brita
    Rowe, Lindsay
    McDonald, Megan
    Kim, Julian O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (02): : 317 - 326